Uveal metastasis: Clinical features and survival outcome of 2214 tumors in 1111 patients based on primary tumor origin
PURPOSE: The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site. METHODS: Retrospective analysis from Wills Eye Hospital, Philadelphia, PA, USA, for uveal metastasis clinical features and outcomes based on the primary tumor site. RESULTS: There were 2214...
Saved in:
| Published in | Middle East African journal of ophthalmology Vol. 25; no. 2; pp. 81 - 90 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
India
Wolters Kluwer India Pvt. Ltd
01.04.2018
Medknow Publications and Media Pvt. Ltd Medknow Publications & Media Pvt. Ltd Medknow Publications & Media Pvt Ltd |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | PURPOSE: The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site.
METHODS: Retrospective analysis from Wills Eye Hospital, Philadelphia, PA, USA, for uveal metastasis clinical features and outcomes based on the primary tumor site.
RESULTS: There were 2214 uveal metastases diagnosed in 1111 consecutive patients. The demographics included mean age of 60 years (median 61 years), Caucasian race (88%), and female gender (64%). The tumor was unilateral (82%) and primary site was established before uveal metastasis (67%). The primary tumor originated in the breast (37%), lung (26%), kidney (4%), gastrointestinal (GI) tract (4%), cutaneous melanoma (2%), lung carcinoid (2%), prostate (2%), thyroid (1%), pancreas (1%), other sites (3%), and unknown (16%). Comparative analysis of the 5 most common primary sites (breast, lung, kidney, GI tract, and cutaneous melanoma), revealed metastasis at mean age (57, 62, 66, 61, 59 years), as unilateral tumor (74%, 86%, 85%, 93%, 85%), with mean number of metastasis/eye (1.9, 1.7, 1.0, 1.1, 2.0), and in females (99%, 46%, 26%, 25%, 30%). Choroidal metastases measured mean base (9.3, 10.2, 9.1, 11.0, 7.3 mm), mean thickness (2.4, 3.6, 4.4, 4.0, 2.9 mm), and demonstrated predominant color yellow (94%, 91%, 56%, 97%, 36%). Of the 769 patients with documented follow-up, mean patient survival was poor (22.2, 11.5, 8.6, 12.4, 11.4 months) and Kaplan-Meier analysis revealed 3-year survival (33%, 19%, 0%, 14%, 21%) and 5-year survival (24%, 13%, 0%, 14%, 21%). The worst survival was found in patients with pancreatic metastasis (mean 4.2 months) and best survival with lung carcinoid (92% at 5 years).
CONCLUSION: In a tertiary referral service, uveal metastasis originates from cancer in the breast, lung, kidney, GI tract, cutaneous melanoma, or others. Overall prognosis is poor with 5-year survival at 23% and worst survival with pancreatic metastasis whereas best survival with lung carcinoid metastasis. |
|---|---|
| AbstractList | PURPOSE: The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site. METHODS: Retrospective analysis from Wills Eye Hospital, Philadelphia, PA, USA, for uveal metastasis clinical features and outcomes based on the primary tumor site. RESULTS: There were 2214 uveal metastases diagnosed in 1111 consecutive patients. The demographics included mean age of 60 years (median 61 years), Caucasian race (88%), and female gender (64%). The tumor was unilateral (82%) and primary site was established before uveal metastasis (67%). The primary tumor originated in the breast (37%), lung (26%), kidney (4%), gastrointestinal (GI) tract (4%), cutaneous melanoma (2%), lung carcinoid (2%), prostate (2%), thyroid (1%), pancreas (1%), other sites (3%), and unknown (16%). Comparative analysis of the 5 most common primary sites (breast, lung, kidney, GI tract, and cutaneous melanoma), revealed metastasis at mean age (57, 62, 66, 61, 59 years), as unilateral tumor (74%, 86%, 85%, 93%, 85%), with mean number of metastasis/eye (1.9, 1.7, 1.0, 1.1, 2.0), and in females (99%, 46%, 26%, 25%, 30%). Choroidal metastases measured mean base (9.3, 10.2, 9.1, 11.0, 7.3 mm), mean thickness (2.4, 3.6, 4.4, 4.0, 2.9 mm), and demonstrated predominant color yellow (94%, 91%, 56%, 97%, 36%). Of the 769 patients with documented follow-up, mean patient survival was poor (22.2, 11.5, 8.6, 12.4, 11.4 months) and Kaplan–Meier analysis revealed 3-year survival (33%, 19%, 0%, 14%, 21%) and 5-year survival (24%, 13%, 0%, 14%, 21%). The worst survival was found in patients with pancreatic metastasis (mean 4.2 months) and best survival with lung carcinoid (92% at 5 years). CONCLUSION: In a tertiary referral service, uveal metastasis originates from cancer in the breast, lung, kidney, GI tract, cutaneous melanoma, or others. Overall prognosis is poor with 5-year survival at 23% and worst survival with pancreatic metastasis whereas best survival with lung carcinoid metastasis. The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site.PURPOSEThe purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site.Retrospective analysis from Wills Eye Hospital, Philadelphia, PA, USA, for uveal metastasis clinical features and outcomes based on the primary tumor site.METHODSRetrospective analysis from Wills Eye Hospital, Philadelphia, PA, USA, for uveal metastasis clinical features and outcomes based on the primary tumor site.There were 2214 uveal metastases diagnosed in 1111 consecutive patients. The demographics included mean age of 60 years (median 61 years), Caucasian race (88%), and female gender (64%). The tumor was unilateral (82%) and primary site was established before uveal metastasis (67%). The primary tumor originated in the breast (37%), lung (26%), kidney (4%), gastrointestinal (GI) tract (4%), cutaneous melanoma (2%), lung carcinoid (2%), prostate (2%), thyroid (1%), pancreas (1%), other sites (3%), and unknown (16%). Comparative analysis of the 5 most common primary sites (breast, lung, kidney, GI tract, and cutaneous melanoma), revealed metastasis at mean age (57, 62, 66, 61, 59 years), as unilateral tumor (74%, 86%, 85%, 93%, 85%), with mean number of metastasis/eye (1.9, 1.7, 1.0, 1.1, 2.0), and in females (99%, 46%, 26%, 25%, 30%). Choroidal metastases measured mean base (9.3, 10.2, 9.1, 11.0, 7.3 mm), mean thickness (2.4, 3.6, 4.4, 4.0, 2.9 mm), and demonstrated predominant color yellow (94%, 91%, 56%, 97%, 36%). Of the 769 patients with documented follow-up, mean patient survival was poor (22.2, 11.5, 8.6, 12.4, 11.4 months) and Kaplan-Meier analysis revealed 3-year survival (33%, 19%, 0%, 14%, 21%) and 5-year survival (24%, 13%, 0%, 14%, 21%). The worst survival was found in patients with pancreatic metastasis (mean 4.2 months) and best survival with lung carcinoid (92% at 5 years).RESULTSThere were 2214 uveal metastases diagnosed in 1111 consecutive patients. The demographics included mean age of 60 years (median 61 years), Caucasian race (88%), and female gender (64%). The tumor was unilateral (82%) and primary site was established before uveal metastasis (67%). The primary tumor originated in the breast (37%), lung (26%), kidney (4%), gastrointestinal (GI) tract (4%), cutaneous melanoma (2%), lung carcinoid (2%), prostate (2%), thyroid (1%), pancreas (1%), other sites (3%), and unknown (16%). Comparative analysis of the 5 most common primary sites (breast, lung, kidney, GI tract, and cutaneous melanoma), revealed metastasis at mean age (57, 62, 66, 61, 59 years), as unilateral tumor (74%, 86%, 85%, 93%, 85%), with mean number of metastasis/eye (1.9, 1.7, 1.0, 1.1, 2.0), and in females (99%, 46%, 26%, 25%, 30%). Choroidal metastases measured mean base (9.3, 10.2, 9.1, 11.0, 7.3 mm), mean thickness (2.4, 3.6, 4.4, 4.0, 2.9 mm), and demonstrated predominant color yellow (94%, 91%, 56%, 97%, 36%). Of the 769 patients with documented follow-up, mean patient survival was poor (22.2, 11.5, 8.6, 12.4, 11.4 months) and Kaplan-Meier analysis revealed 3-year survival (33%, 19%, 0%, 14%, 21%) and 5-year survival (24%, 13%, 0%, 14%, 21%). The worst survival was found in patients with pancreatic metastasis (mean 4.2 months) and best survival with lung carcinoid (92% at 5 years).In a tertiary referral service, uveal metastasis originates from cancer in the breast, lung, kidney, GI tract, cutaneous melanoma, or others. Overall prognosis is poor with 5-year survival at 23% and worst survival with pancreatic metastasis whereas best survival with lung carcinoid metastasis.CONCLUSIONIn a tertiary referral service, uveal metastasis originates from cancer in the breast, lung, kidney, GI tract, cutaneous melanoma, or others. Overall prognosis is poor with 5-year survival at 23% and worst survival with pancreatic metastasis whereas best survival with lung carcinoid metastasis. PURPOSE: The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site. METHODS: Retrospective analysis from Wills Eye Hospital, Philadelphia, PA, USA, for uveal metastasis clinical features and outcomes based on the primary tumor site. RESULTS: There were 2214 uveal metastases diagnosed in 1111 consecutive patients. The demographics included mean age of 60 years (median 61 years), Caucasian race (88%), and female gender (64%). The tumor was unilateral (82%) and primary site was established before uveal metastasis (67%). The primary tumor originated in the breast (37%), lung (26%), kidney (4%), gastrointestinal (GI) tract (4%), cutaneous melanoma (2%), lung carcinoid (2%), prostate (2%), thyroid (1%), pancreas (1%), other sites (3%), and unknown (16%). Comparative analysis of the 5 most common primary sites (breast, lung, kidney, GI tract, and cutaneous melanoma), revealed metastasis at mean age (57, 62, 66, 61, 59 years), as unilateral tumor (74%, 86%, 85%, 93%, 85%), with mean number of metastasis/eye (1.9, 1.7, 1.0, 1.1, 2.0), and in females (99%, 46%, 26%, 25%, 30%). Choroidal metastases measured mean base (9.3, 10.2, 9.1, 11.0, 7.3 mm), mean thickness (2.4, 3.6, 4.4, 4.0, 2.9 mm), and demonstrated predominant color yellow (94%, 91%, 56%, 97%, 36%). Of the 769 patients with documented follow-up, mean patient survival was poor (22.2, 11.5, 8.6, 12.4, 11.4 months) and Kaplan-Meier analysis revealed 3-year survival (33%, 19%, 0%, 14%, 21%) and 5-year survival (24%, 13%, 0%, 14%, 21%). The worst survival was found in patients with pancreatic metastasis (mean 4.2 months) and best survival with lung carcinoid (92% at 5 years). CONCLUSION: In a tertiary referral service, uveal metastasis originates from cancer in the breast, lung, kidney, GI tract, cutaneous melanoma, or others. Overall prognosis is poor with 5-year survival at 23% and worst survival with pancreatic metastasis whereas best survival with lung carcinoid metastasis. The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site. Retrospective analysis from Wills Eye Hospital, Philadelphia, PA, USA, for uveal metastasis clinical features and outcomes based on the primary tumor site. There were 2214 uveal metastases diagnosed in 1111 consecutive patients. The demographics included mean age of 60 years (median 61 years), Caucasian race (88%), and female gender (64%). The tumor was unilateral (82%) and primary site was established before uveal metastasis (67%). The primary tumor originated in the breast (37%), lung (26%), kidney (4%), gastrointestinal (GI) tract (4%), cutaneous melanoma (2%), lung carcinoid (2%), prostate (2%), thyroid (1%), pancreas (1%), other sites (3%), and unknown (16%). Comparative analysis of the 5 most common primary sites (breast, lung, kidney, GI tract, and cutaneous melanoma), revealed metastasis at mean age (57, 62, 66, 61, 59 years), as unilateral tumor (74%, 86%, 85%, 93%, 85%), with mean number of metastasis/eye (1.9, 1.7, 1.0, 1.1, 2.0), and in females (99%, 46%, 26%, 25%, 30%). Choroidal metastases measured mean base (9.3, 10.2, 9.1, 11.0, 7.3 mm), mean thickness (2.4, 3.6, 4.4, 4.0, 2.9 mm), and demonstrated predominant color yellow (94%, 91%, 56%, 97%, 36%). Of the 769 patients with documented follow-up, mean patient survival was poor (22.2, 11.5, 8.6, 12.4, 11.4 months) and Kaplan-Meier analysis revealed 3-year survival (33%, 19%, 0%, 14%, 21%) and 5-year survival (24%, 13%, 0%, 14%, 21%). The worst survival was found in patients with pancreatic metastasis (mean 4.2 months) and best survival with lung carcinoid (92% at 5 years). In a tertiary referral service, uveal metastasis originates from cancer in the breast, lung, kidney, GI tract, cutaneous melanoma, or others. Overall prognosis is poor with 5-year survival at 23% and worst survival with pancreatic metastasis whereas best survival with lung carcinoid metastasis. |
| Audience | Academic |
| Author | McGarrey, Mark Malik, Kunal Acaba-Berrocal, Luis Shields, Jerry Knapp, Austen Graf, Alexander Shields, Carol Constantinescu, Alexandru Welch, R Considine, Sean Newman, Jennifer Altman, Alex Mayro, Eileen Spencer, Meredith Selzer, Evan |
| AuthorAffiliation | Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA |
| AuthorAffiliation_xml | – name: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA |
| Author_xml | – sequence: 1 givenname: Carol surname: Shields fullname: Shields, Carol organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA – sequence: 2 givenname: R surname: Welch fullname: Welch, R organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA – sequence: 3 givenname: Kunal surname: Malik fullname: Malik, Kunal organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA – sequence: 4 givenname: Luis surname: Acaba-Berrocal fullname: Acaba-Berrocal, Luis organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA – sequence: 5 givenname: Evan surname: Selzer fullname: Selzer, Evan organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA – sequence: 6 givenname: Jennifer surname: Newman fullname: Newman, Jennifer organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA – sequence: 7 givenname: Eileen surname: Mayro fullname: Mayro, Eileen organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA – sequence: 8 givenname: Alexandru surname: Constantinescu fullname: Constantinescu, Alexandru organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA – sequence: 9 givenname: Meredith surname: Spencer fullname: Spencer, Meredith organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA – sequence: 10 givenname: Mark surname: McGarrey fullname: McGarrey, Mark organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA – sequence: 11 givenname: Austen surname: Knapp fullname: Knapp, Austen organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA – sequence: 12 givenname: Alexander surname: Graf fullname: Graf, Alexander organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA – sequence: 13 givenname: Alex surname: Altman fullname: Altman, Alex organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA – sequence: 14 givenname: Sean surname: Considine fullname: Considine, Sean organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA – sequence: 15 givenname: Jerry surname: Shields fullname: Shields, Jerry organization: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30122853$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt1v2yAUxa2p09p1fd_ThDRp2ksyMMY2e6gURV23qVNf1mdE8CUhxdABTrT_fuSjH6m2YUtY179zuMB5XRw576Ao3hI8rgimn3qQSz_-cTH5fi1qQdoXxQnmDRsRxvnR9rsa8ZLS4-IsxiXejAY3rH1VHFNMyrJl9KRY3axAWtRDkjG_Jn5GU2ucUbmoQaYhQETSdSgOYWVWueqHpHwPyGtUlqRCaeh9iMg4RPJAdzIZcCmimYzQIe_QXTC9DL93IPLBzI17U7zU0kY428-nxc2Xi5_Tr6Or68tv08nVSLG2jiOQWEvgvOV6BlLruu1aVZESa01lVzKuJIGKzTpW44bWlWStKhXnpGmwJJrT0-J853s3zHroVO4sSCv2LQkvjTj848xCzP1KZD9CqzIbfNwbBP9rgJhEb6ICa6UDP0RRYo4pzR2xjL5_hi79EFzeXqYazuumZvUjNZcWhHHa53XVxlRMWNXQqiVbavwXKj8d9EblHGiT6weCD08Ei3ynaRG9HZLxLh6C756eyMNR3EciA3gHqOBjDKAfEILFJnhiGzzxGLwsqZ9JlElys3Tu2tj_CS93wrW3CUK8tcMaQua6W-fX_9SJlohtbsV9bukfSIb3wQ |
| CitedBy_id | crossref_primary_10_1038_s41598_024_64464_z crossref_primary_10_1136_bjophthalmol_2018_313680 crossref_primary_10_1007_s00347_018_0840_8 crossref_primary_10_1097_IIO_0000000000000332 crossref_primary_10_1097_ICU_0000000000000550 crossref_primary_10_3389_fgene_2022_1010903 crossref_primary_10_1016_j_ajoc_2022_101459 crossref_primary_10_2147_OPTH_S285250 crossref_primary_10_1155_2020_8862203 crossref_primary_10_24875_RMO_M21000165 crossref_primary_10_1007_s11604_022_01362_2 crossref_primary_10_1016_j_jcjo_2023_04_013 crossref_primary_10_1001_jamaophthalmol_2022_3453 crossref_primary_10_1016_j_jfo_2020_05_026 crossref_primary_10_1016_j_oftale_2020_05_033 crossref_primary_10_1097_MD_0000000000027693 crossref_primary_10_1016_j_oftal_2020_05_039 crossref_primary_10_18502_jovr_v15i4_7793 crossref_primary_10_4103_IJO_IJO_1189_23 crossref_primary_10_1016_j_eucr_2024_102814 crossref_primary_10_1016_j_jfo_2020_04_066 crossref_primary_10_1111_ceo_14328 crossref_primary_10_1097_IAE_0000000000003038 crossref_primary_10_1097_IAE_0000000000003433 crossref_primary_10_1002_cnr2_1347 crossref_primary_10_1016_j_ajoc_2023_101945 crossref_primary_10_1016_j_cllc_2022_07_018 crossref_primary_10_1159_000544159 crossref_primary_10_1111_ceo_13904 crossref_primary_10_1038_s41433_022_02015_4 crossref_primary_10_1001_jama_2019_12691 crossref_primary_10_1016_j_jfo_2022_05_010 crossref_primary_10_12968_opti_2024_270_6966_24 crossref_primary_10_1016_j_oret_2020_12_025 crossref_primary_10_1016_j_sjopt_2019_07_006 crossref_primary_10_3390_medicina57060539 crossref_primary_10_1016_j_ajoc_2021_101190 crossref_primary_10_1186_s13000_024_01553_7 crossref_primary_10_1002_ccr3_5729 crossref_primary_10_1016_j_jcjo_2023_09_010 crossref_primary_10_1016_j_patol_2025_100805 crossref_primary_10_1111_ceo_13889 crossref_primary_10_1177_1533033820984180 crossref_primary_10_1097_ICB_0000000000001176 crossref_primary_10_1097_ICB_0000000000001495 crossref_primary_10_4103_tjo_tjo_59_20 crossref_primary_10_1080_09273948_2021_1939392 crossref_primary_10_1038_s41433_020_01151_z crossref_primary_10_1080_09273948_2024_2447846 crossref_primary_10_29413_ABS_2022_7_3_21 crossref_primary_10_1016_j_oret_2020_09_007 crossref_primary_10_3389_fonc_2024_1516783 crossref_primary_10_4103_erj_erj_8_24 crossref_primary_10_7759_cureus_24243 crossref_primary_10_1016_j_oret_2019_10_009 crossref_primary_10_1007_s00347_019_00956_y crossref_primary_10_1016_j_jcjo_2020_04_023 crossref_primary_10_1017_cjn_2022_17 crossref_primary_10_1017_S1460396920001090 crossref_primary_10_1016_j_jcjo_2024_12_002 crossref_primary_10_4103_pajo_pajo_41_23 crossref_primary_10_1177_11206721241236528 crossref_primary_10_1097_IAE_0000000000002364 crossref_primary_10_1016_j_ajoc_2022_101269 crossref_primary_10_1159_000494979 crossref_primary_10_7759_cureus_77835 crossref_primary_10_5114_oku_193828 crossref_primary_10_1007_s00347_024_02031_7 crossref_primary_10_1097_MD_0000000000022773 crossref_primary_10_4103_ijo_IJO_58_20 crossref_primary_10_1002_ccr3_4790 crossref_primary_10_1016_j_ajoc_2024_102035 crossref_primary_10_1001_jamaophthalmol_2022_5544 crossref_primary_10_1097_APO_0000000000000247 crossref_primary_10_2147_CMAR_S345078 |
| Cites_doi | 10.1016/j.ophtha.2011.02.004 10.1001/archopht.1974.01010010286003 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2018 Medknow Publications and Media Pvt. Ltd. 2018. This work is published under https://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright: © 2018 Middle East African Journal of Ophthalmology 2018 |
| Copyright_xml | – notice: COPYRIGHT 2018 Medknow Publications and Media Pvt. Ltd. – notice: 2018. This work is published under https://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright: © 2018 Middle East African Journal of Ophthalmology 2018 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. M0S M1P M2O MBDVC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.4103/meajo.MEAJO_6_18 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 0975-1599 0974-9233 |
| EndPage | 90 |
| ExternalDocumentID | PMC6071342 A547348156 30122853 10_4103_meajo_MEAJO_6_18 10.4103/meajo.MEAJO_6_18_81_Uveal metastas |
| Genre | Journal Article |
| GroupedDBID | --- 29M 2WC 5VS 7X7 88E 8FI 8FJ 8G5 ABDBF ABJNI ABUWG ACGFS ACUHS ADBBV ADJBI AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BENPR BPHCQ BVXVI CCPQU DIK DWQXO E3Z EBD EJD EOJEC ESX F5P FYUFA GNUQQ GUQSH GX1 H13 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M2O M48 O5R O5S OBODZ OK1 OVD P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RMW RNS RPM TEORI TR2 TUS UKHRP W3E AAYXX ABXLX ADRAZ CITATION IL9 3V. CGR CUY CVF ECM EIF GROUPED_DOAJ M~E NPM PMFND 7XB 8FK K9. MBDVC PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c586s-ea0fae9989fbeaff68d8c4120ff3ad259ca1e45bd5607364a58c2c991770a1f93 |
| IEDL.DBID | M48 |
| ISSN | 0974-9233 0975-1599 |
| IngestDate | Thu Aug 21 14:33:05 EDT 2025 Mon Jul 21 11:55:48 EDT 2025 Fri Jul 25 21:31:57 EDT 2025 Tue Jun 17 21:21:17 EDT 2025 Tue Jun 10 20:31:20 EDT 2025 Thu May 22 21:21:28 EDT 2025 Wed Feb 19 02:44:09 EST 2025 Tue Jul 01 03:47:59 EDT 2025 Thu Apr 24 22:56:01 EDT 2025 Tue Jun 17 22:46:05 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | eye Choroid iris uvea ciliary body metastasis |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c586s-ea0fae9989fbeaff68d8c4120ff3ad259ca1e45bd5607364a58c2c991770a1f93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2079967656?pq-origsite=%requestingapplication% |
| PMID | 30122853 |
| PQID | 2079967656 |
| PQPubID | 226464 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6071342 proquest_miscellaneous_2090331205 proquest_journals_2079967656 gale_infotracmisc_A547348156 gale_infotracacademiconefile_A547348156 gale_healthsolutions_A547348156 pubmed_primary_30122853 crossref_primary_10_4103_meajo_MEAJO_6_18 crossref_citationtrail_10_4103_meajo_MEAJO_6_18 wolterskluwer_medknow_10_4103_meajo_MEAJO_6_18_81_Uveal_metastas |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20180401 |
| PublicationDateYYYYMMDD | 2018-04-01 |
| PublicationDate_xml | – month: 4 year: 2018 text: 20180401 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | India |
| PublicationPlace_xml | – name: India – name: Riyadh |
| PublicationTitle | Middle East African journal of ophthalmology |
| PublicationTitleAlternate | Middle East Afr J Ophthalmol |
| PublicationYear | 2018 |
| Publisher | Wolters Kluwer India Pvt. Ltd Medknow Publications and Media Pvt. Ltd Medknow Publications & Media Pvt. Ltd Medknow Publications & Media Pvt Ltd |
| Publisher_xml | – name: Wolters Kluwer India Pvt. Ltd – name: Medknow Publications and Media Pvt. Ltd – name: Medknow Publications & Media Pvt. Ltd – name: Medknow Publications & Media Pvt Ltd |
| References | Rudoler (key-10.4103/0974-9233.237037-16) 1997 Stephens (key-10.4103/0974-9233.237037-3) 1979 Shields (key-10.4103/0974-9233.237037-6) 2015 Shields (key-10.4103/0974-9233.237037-1) 1997 Demirci (key-10.4103/0974-9233.237037-10) 2003 Rudoler (key-10.4103/0974-9233.237037-17) 1997 Shields (key-10.4103/0974-9233.237037-5) 1995 Konstantinidis (key-10.4103/0974-9233.237037-8) 2017 key-10.4103/0974-9233.237037-9 Shields (key-10.4103/0974-9233.237037-18) 1997 Arepalli (key-10.4103/0974-9233.237037-7) 2015 de (key-10.4103/0974-9233.237037-13) 1985 Harbour (key-10.4103/0974-9233.237037-15) 1994 key-10.4103/0974-9233.237037-2 Shah (key-10.4103/0974-9233.237037-11) 2014 key-10.4103/0974-9233.237037-12 Zografos (key-10.4103/0974-9233.237037-14) 2004 Kaliki (key-10.4103/0974-9233.237037-19) 2012 Freedman (key-10.4103/0974-9233.237037-4) 1987 3307718 - Arch Ophthalmol. 1987 Sep;105(9):1215-9 8008351 - Ophthalmology. 1994 Jun;101(6):1084-90 9226310 - Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):251-6 15564763 - Ophthalmologica. 2004 Nov-Dec;218(6):424-33 22386261 - Ophthalmology. 2012 Jun;119(6):1218-22 4015484 - Arch Ophthalmol. 1985 Jul;103(7):937-40 25827542 - Indian J Ophthalmol. 2015 Feb;63(2):122-7 9261313 - Ophthalmology. 1997 Aug;104(8):1265-76 7709967 - Am J Ophthalmol. 1995 Apr;119(4):422-30 9046255 - Arch Ophthalmol. 1997 Feb;115(2):203-9 28399345 - Asia Pac J Ophthalmol (Phila). 2017 Mar-Apr;6(2):208-214 12888048 - Am J Ophthalmol. 2003 Aug;136(2):264-71 233866 - Ophthalmology. 1979 Jul;86(7):1336-49 4412321 - Arch Ophthalmol. 1974 Oct;92(4):276-86 9060569 - J Clin Oncol. 1997 Mar;15(3):1244-51 21724049 - Ophthalmology. 2011 Jul;118(7):1483-1483.e4 23988200 - Ophthalmology. 2014 Jan;121(1):352-357 25343701 - Cornea. 2015 Jan;34(1):42-8 |
| References_xml | – start-page: 422 volume-title: Metastatic tumors to the iris in 40 patients year: 1995 ident: key-10.4103/0974-9233.237037-5 publication-title: Am J Ophthalmol – start-page: 1218 volume-title: Photodynamic therapy for choroidal metastasis in 8 cases year: 2012 ident: key-10.4103/0974-9233.237037-19 publication-title: Ophthalmology – start-page: 424 volume-title: Systemic melanoma metastatic to the retina and vitreous year: 2004 ident: key-10.4103/0974-9233.237037-14 publication-title: Ophthalmologica – start-page: 264 volume-title: Uveal metastasis from breast cancer in 264 patients year: 2003 ident: key-10.4103/0974-9233.237037-10 publication-title: Am J Ophthalmol – ident: key-10.4103/0974-9233.237037-12 doi: 10.1016/j.ophtha.2011.02.004 – start-page: 251 volume-title: External beam irradiation for choroid metastases: Identification of factors predisposing to long-term sequelae year: 1997 ident: key-10.4103/0974-9233.237037-16 publication-title: Int J Radiat Oncol Biol Phys – start-page: 42 volume-title: Iris metastasis from systemic cancer in 104 patients: The 2014 Jerry A.Shields Lecture year: 2015 ident: key-10.4103/0974-9233.237037-6 publication-title: Cornea – start-page: 203 volume-title: Plaque radiotherapy for the management of uveal metastasis year: 1997 ident: key-10.4103/0974-9233.237037-18 publication-title: Arch Ophthalmol – start-page: 208 volume-title: Intraocular metastases – A review year: 2017 ident: key-10.4103/0974-9233.237037-8 publication-title: Asia Pac J Ophthalmol (Phila) – ident: key-10.4103/0974-9233.237037-2 doi: 10.1001/archopht.1974.01010010286003 – start-page: 122 issn: 0301-4738 volume-title: Choroidal metastases: Origin, features, and therapy year: 2015 ident: key-10.4103/0974-9233.237037-7 publication-title: Indian J Ophthalmol – start-page: 352 volume-title: Uveal metastasis from lung cancer: Clinical features, treatment, and outcome in 194 patients year: 2014 ident: key-10.4103/0974-9233.237037-11 publication-title: Ophthalmology – start-page: 937 volume-title: Intraocular metastases from cutaneous malignant melanoma year: 1985 ident: key-10.4103/0974-9233.237037-13 publication-title: Arch Ophthalmol – start-page: 1244 volume-title: , et al. Functional vision is improved in the majority of patients treated with external-beam radiotherapy for choroid metastases: A multivariate analysis of 188 patients year: 1997 ident: key-10.4103/0974-9233.237037-17 publication-title: J Clin Oncol – start-page: 1336 volume-title: Diagnosis and management of cancer metastatic to the uvea: A study of 70 cases year: 1979 ident: key-10.4103/0974-9233.237037-3 publication-title: Ophthalmology – start-page: 1084 volume-title: Uveal metastasis from carcinoid tumor.Clinical observations in nine cases year: 1994 ident: key-10.4103/0974-9233.237037-15 publication-title: Ophthalmology – ident: key-10.4103/0974-9233.237037-9 – start-page: 1265 volume-title: Survey of 520 eyes with uveal metastases year: 1997 ident: key-10.4103/0974-9233.237037-1 publication-title: Ophthalmology – start-page: 1215 volume-title: Metastatic tumors to the eye and orbit.Patient survival and clinical characteristics year: 1987 ident: key-10.4103/0974-9233.237037-4 publication-title: Arch Ophthalmol – reference: 28399345 - Asia Pac J Ophthalmol (Phila). 2017 Mar-Apr;6(2):208-214 – reference: 4412321 - Arch Ophthalmol. 1974 Oct;92(4):276-86 – reference: 12888048 - Am J Ophthalmol. 2003 Aug;136(2):264-71 – reference: 25827542 - Indian J Ophthalmol. 2015 Feb;63(2):122-7 – reference: 9226310 - Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):251-6 – reference: 233866 - Ophthalmology. 1979 Jul;86(7):1336-49 – reference: 7709967 - Am J Ophthalmol. 1995 Apr;119(4):422-30 – reference: 9046255 - Arch Ophthalmol. 1997 Feb;115(2):203-9 – reference: 8008351 - Ophthalmology. 1994 Jun;101(6):1084-90 – reference: 22386261 - Ophthalmology. 2012 Jun;119(6):1218-22 – reference: 4015484 - Arch Ophthalmol. 1985 Jul;103(7):937-40 – reference: 21724049 - Ophthalmology. 2011 Jul;118(7):1483-1483.e4 – reference: 15564763 - Ophthalmologica. 2004 Nov-Dec;218(6):424-33 – reference: 25343701 - Cornea. 2015 Jan;34(1):42-8 – reference: 3307718 - Arch Ophthalmol. 1987 Sep;105(9):1215-9 – reference: 23988200 - Ophthalmology. 2014 Jan;121(1):352-357 – reference: 9060569 - J Clin Oncol. 1997 Mar;15(3):1244-51 – reference: 9261313 - Ophthalmology. 1997 Aug;104(8):1265-76 |
| SSID | ssj0000070758 |
| Score | 2.4184318 |
| Snippet | PURPOSE: The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site.
METHODS: Retrospective analysis from Wills Eye... The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site. Retrospective analysis from Wills Eye Hospital,... PURPOSE: The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site. METHODS: Retrospective analysis from Wills Eye... The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site.PURPOSEThe purpose of this study is to evaluate patients... |
| SourceID | pubmedcentral proquest gale pubmed crossref wolterskluwer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 81 |
| SubjectTerms | Adolescent Adult Aged Aged, 80 and over Breast cancer Cancer metastasis Child Choroid - pathology Ciliary Body - pathology Diagnostic Techniques, Ophthalmological Female Humans Iris - pathology Kidney cancer Lung cancer Male Medical prognosis Medical research Medical screening Melanoma Metastasis Middle Aged Neoplasm Metastasis - diagnosis Neoplasm Staging Ophthalmology Original Pancreas Patient outcomes Patients Pennsylvania - epidemiology Prognosis Prostate Radiation therapy Retrospective Studies Survival Rate - trends Thyroid gland Tumors Uveal Neoplasms - diagnosis Uveal Neoplasms - mortality Uveal Neoplasms - secondary Young Adult |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSAgJId4EChgJCXEIzcOxEy6wQq2qSgsXVtqb5Ti2utBNSp0tf58Zx5tuKtGzJw-P52XP-BtC3jPFq0prLGJIWcxqzuKqzJu4SnLb5MKAC8YD_fl3frxgJ8tiGQ7cXCir3NpEb6ibTuMZOZ6EQGguIPz4cv4nxq5RmF0NLTRukzsIXYYlXWIpxjMWj2XjW3QmlShi8NzVkKlkaZIfrI361X2aH85OfkgusevHjme6bp93HNT14sn7fztMbLvfvq59xzsdPSQPQlhJZ4McPCK3TPuY3J2HxPkTcrm4hIiQrk2vIBx0K_eZBkTQM2qNB_d0VLUNdRuwHSB9tNv0wBhDO0uzLGW036y7C0dXLUXzRwMeq6PoBhvatfR8wK0YCOnQcOspWRwd_vx2HIeWC7EuSu5ioxKrDGzBKlsbZS0vm1KzNEuszVUDWyWtUsOKuoFASeScqaLUmYYYU4hEpbbKn5G9tmvNC0KFMKzhZS2sgTcUdV0VTNi6sExntuZNRA627JY64JFjW4wzCfsSXCDpF0heLVBEPo5PhDndQPsWV1AOt0lHNZYz7LXsIXIi8sFToCLDd7UK9xHg7xESa0K5P6EEBdTT4a2UyGAAnLwS14i8G4fxSSxqa023QRrQiByYW0Tk-SBU47xyTHlCKBURMRG3kQBhwacj7erUw4Nzfz84i8jXiWACi_z9yv-yTJap9MIot8L48uaZvSL3IHwshzqmfbLXX2zMawjR-vqN18N_s_s-Kw priority: 102 providerName: ProQuest – databaseName: Medknow Open Access Journals dbid: W3E link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9UwFA9jgggifludGkEQH8raJE1a--JFNsbg6ovDvYU0TdjVe1tZ24n_vSdJb3c70Befc5rm43zl5OR3EHrLFC8KrV0SQ8piVnEWFzmt4yKhtqbCgAl2Af3lZ35yxk7Ps_M9tI0quazKjVHf2wARHBbPP-kag1YC-iKUlr-BD1x8Ly9HKSZZGUZKyiCKeVoGhV4kpRrAFe19eel13ZUejwjO-beIIJnLA_tGrwMzHgDH1_Wc_hauN1ma0MMwuOXR4vSL5NKVCtkxZzeV-o5Vu5lxefdX627Dux8-GX7HpB3fR_dGXxQvwvwfoD3TPES3l-Nt-yN0dXYFbiTemB6mpbpV9wGPMKJrbI1HBO2wamrcDaBwgGVxO_TAwQa3FhOSMtwPm_ayw6sGO52JRxDXDjvbWeO2wT8D2EUgxKFK12N0dnz09dNJPNZpiHWW8y42KrHKwLmtsJVR1vK8zjVLSWItVTWcr7RKDcuqGrwrQTlTWa6JBsdUiESltqBP0H7TNuYZwkIYVvO8EtZAD1lVFRkTtsos08RWvI7Q4Xa5pR5BzF0tjbWEw4zbIOk3SF5vUITeT1-Mc_oH7Wu3gzI8QZ1kXy5cgWaPqxOhd57CST_8V6vxEQOM3uFozSgPZpQgtXrevOUSOWqNTpJEwPFTcNf8Zmp2X7pMuMa0g6MBMaKwuFmEngammuZF3T0p-F8REjN2mwgclvi8pVldeExx7h8Vkwh9nDEmLJF_lPnXJZN5Kj0zyi0zPv__Ll6gO060Q4LUAdrvLwfzEny_vnrlZfUPU-ddJQ priority: 102 providerName: Wolters Kluwer Health |
| Title | Uveal metastasis: Clinical features and survival outcome of 2214 tumors in 1111 patients based on primary tumor origin |
| URI | http://www.meajo.org/article.asp?issn=0974-9233;year=2018;volume=25;issue=2;spage=81;epage=90;aulast=Shields;type=0 https://www.ncbi.nlm.nih.gov/pubmed/30122853 https://www.proquest.com/docview/2079967656 https://www.proquest.com/docview/2090331205 https://pubmed.ncbi.nlm.nih.gov/PMC6071342 |
| Volume | 25 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwELbYJiEkhPg5AqMYCQnxkC6JHTvhBQrqNE3qQIiKvlmOY4tCm0CTDPjvOTtptkwDiZe--JI05-9838W-O4SeU8nSVCl7iCGkPs0Y9dOE5H4aEJMTrsEF2w_6s1N2PKcni3hxnh7dKbC6MrSz_aTmm9X414_fr8Hggb-OaRiQw7WWX8vxbDo5eS-YCJMdtAd-iVsznXVkvyXDHPyjW5qBRPvAbEi7b3nlTQZ-6vJqfcFdXT5KefNnabe5q2_ulPsFX3V0G93qSCaetKi4g67p4i66Puu20e-hs_kZ8EO81rUEclgtq1e4qw-6wka7Up8VlkWOqwZWEsAiLpsaoKlxaXAUhRTXzbrcVHhZYLsY4q46a4WtU8xxWeDvbRWLVhC37bfuo_nR9NO7Y79rwOCrOGGVr2VgpIaALDWZlsawJE8UDaPAGCJzCJyUDDWNsxxoEyeMyjhRkQLGyXkgQ5OSB2i3KAv9EGHONc1ZknGj4Q5xlqUx5SaLDVWRyVjuocOtuoXqqpPbJhkrAVGKnSDhJkicT5CHXvZXdO_0D9mndgZFm1vaG7WY2M7LrmCOh144CQs0eK6SXXYC_HtbIGsgeTCQBHNUw-EtSsQWzSIKOMSVnNnhZ_2wvdIecSt02VgZsA8Cyo09tN-Cqn8vYjdAgVh5iA_g1gvYIuHDkWL5xRULZy5bOPLQmwEwQUUu2_KvKhNJKBwYxRaMj_5D4Y_RDWCWSXvE6QDt1ptGPwH2VmcjtMMXfIT23k5PP3wcOROF389k-gfSV0pn |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELaqrQRICHETKNRIIMRDaA7nQkKwwFbbYxeEulLfjOPYYqGblGbTij_Fb2TGObqpRN_67Mlhz3jmsz3-hpAXTIRJIiUmMbjMZmnI7CT2MztxfJ35kYIQjBv6k2k4nrHdw-Bwjfxt78JgWmXrE42jzgqJe-S4EwLQPAL48f74t41Vo_B0tS2hUZvFnvpzBku28t3OZ9DvS8_bHh18GttNVQFbBnFY2ko4WihYZSQ6VULrMM5iyVzP0doXGawGpHAVC9IMsEDkh0wEsfQkwKgocoSrkXwJXP4682EpMyDrH0fTr9-6XR3DnmOKgjpJFNiAFZL6bJS5jr-1UOJn8WYyGu5-4SHHOiMrsfBiRFgJiRfTNW-eFXiUXv4ymfQr8XD7NrnVAFk6rC3vDllT-V1ybdIc1d8jp7NTwKB0oZYCAGg5L9_ShoP0iGpl6ERLKvKMlhV4K7B3WlRLUIWihaae5zK6rBbFSUnnOUWHSxsG2JJi4M1okdPjmimjFqR1ia_7ZHYl6nhABnmRq0eERpFiWRinkVbwhiBNk4BFOg00k55Ow8wiW-1wc9kwoGMhjiMOKyFUEDcK4ucKssjr7ommT5fIbqIGeX1_tXMcfIjVnQ0pj0VeGQl0HfBdKZobEPD3SMLVk9zoScKUl_3m1kp443JKfj5BLPK8a8YnMY0uV0WFMjAHfRjcwCIPa6Pq-uXjISuAN4tEPXPrBJCIvN-Sz38YQvLQ3Ej2LPKhZ5gwROZG53-HjMcuN8bIW2N8fHnPNsn18cFkn-_vTPeekBsAXuM6i2qDDJYnlXoKAHGZPmtmJSXfr9oR_AM9un2A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Uveal+metastasis%3A+Clinical+features+and+survival+outcome+of+2214+tumors+in+1111+patients+based+on+primary+tumor+origin&rft.jtitle=Middle+East+African+journal+of+ophthalmology&rft.au=Shields%2C+CarolL&rft.au=Welch%2C+RJoel&rft.au=Malik%2C+Kunal&rft.au=Acaba-Berrocal%2C+LuisA&rft.date=2018-04-01&rft.issn=0974-9233&rft.volume=25&rft.issue=2&rft.spage=81&rft_id=info:doi/10.4103%2Fmeajo.MEAJO_6_18&rft.externalDBID=n%2Fa&rft.externalDocID=10_4103_meajo_MEAJO_6_18 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0974-9233&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0974-9233&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0974-9233&client=summon |